transmembrane 9 superfamily member 2Genealiases: Lnc-PCIR · P76
Q-omics provides the consensus-scored TM9SF2 profile across patient tissues and cancer cell-line models. TM9SF2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TM9SF2 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, TM9SF2 protein abundance shows 20,487 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, KICH, and PDAC as cancer lineages where TM9SF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TM9SF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TM9SF2 survival associations across molecular data types. TM9SF2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TM9SF2 RNA expression–survival associations across cancer types. High TM9SF2 expression shows unfavorable associations in HNSC, UVM, ACC, ESCA and CESC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TM9SF2 RNA expression.
This table summarizes TM9SF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TM9SF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TM9SF2 shows lower tumor expression in KICH, THCA and KIRC and higher tumor expression in STAD, BLCA and HNSC. The KICH box plot shows higher TM9SF2 RNA expression in normal versus tumor tissue (log2 FC = −0.995, t-test p < 0.001).
This table shows molecular features associated with TM9SF2 in patient tissues and cancer cell lines. In patient samples, TM9SF2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TM9SF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
